Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Seeking Alpha
TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive stronger growth in Q4'25 and beyond. TARS pipeline includes international Xdemvy launches and a new ocular rosacea trial, offering significant future revenue potential beyond current indications. Martinns/E+ via Getty Images Tarsus Pharmaceuticals ( NASDAQ: TARS ) is now two years into the launch of Xdemvy (lotilaner) for Demodex blepharitis, and while sales have passed $100M per quarter, so has SG&A. In May, I rated TARS a buy, noting their "Get Big Fast" approach This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TARS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this artic
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]Yahoo! Finance
- Tarsus to Participate in Upcoming Investor ConferenceGlobeNewswire
- Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]Seeking Alpha
- Tarsus Pharmaceuticals (NASDAQ:TARS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $100.00 price target on the stock.MarketBeat
- Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
TARS
Earnings
- 11/4/25 - Beat
TARS
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- TARS's page on the SEC website